Shares of Alterity Therapeutics Ltd (NASDAQ:ATHE) climbed 3.3% in premarket trading on Thursday after the company unveiled promising clinical data from its Phase 2 trial for Multiple System Atrophy (MSA) during a key medical conference.
The biotech firm shared the results of its ATH434-201 randomized, double-blind study at the International Congress of Parkinson’s Disease and Movement Disorders 2025 in Honolulu. The findings highlighted ATH434’s potential as a disease-modifying therapy for MSA, demonstrating a slower rate of disease progression and improved stabilization of orthostatic hypotension, a particularly difficult symptom to manage in MSA patients.
Among the notable results was a clinically meaningful reduction in disease severity versus placebo on the modified UMSARS I daily living scale. The 50 mg dose produced a 48% relative treatment effect (p=0.02), while the 75 mg dose achieved a 30% effect at 52 weeks.
“The aggregate data from our double-blind trial continue to demonstrate the potential of ATH434 as a disease modifying therapy for MSA,” said David Stamler, M.D., Chief Executive Officer of Alterity.
Further analysis revealed that when adjusting for baseline differences in orthostatic hypotension, the efficacy signal at 75 mg grew stronger, reaching a 35% relative treatment effect on the primary clinical endpoint. Secondary measures supported these results, showing consistent improvements on the Clinical Global Impression of Severity Scale and increased activity levels recorded via wearable movement sensors.
The company also shared neuroimaging biomarker data indicating that ATH434 reduced iron buildup in key brain regions compared to placebo, confirming target engagement. The treatment was well tolerated, with adverse events comparable to placebo.
Alterity Therapeutics stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.